Stockscreener 앱 받기
12.12
0.98%
-0.12
시간 외 거래:
12.12
Design Therapeutics Inc 주식(DSGN)의 최신 뉴스
Cullinan Therapeutics, Inc. (CGEM) stock price, news, quote and history - Yahoo Finance Singapore
Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis - manilatimes.net
BigHat Biosciences Announces $75 Million Series C Financing to Advance AI-Designed Therapeutics and Leading Agentic Data Platform for Rapid Protein Design - Business Wire
/C O R R E C T I O N -- Basecamp Research/ - PR Newswire
Cullinan Therapeutics, Inc. (CGEM) Stock Price, News, Quote & History - Yahoo! Finance Canada
Basecamp Research raises $140 million to advance AI-designed cell therapies - The Pharma Letter
Design Therapeutics, Inc.(NasdaqGS:DSGN) added to S&P Biotechnology Select Industry Index - marketscreener.com
Design Therapeutics at Cantor conference: biomarker push takes center stage By Investing.com - Investing.com India
Design Therapeutics at Cantor conference: biomarker push takes center stage - Investing.com
DSGN: DT-216 achieved robust biomarker and clinical gains in FA, with pivotal data expected in Q1 2027 - TradingView
Design Therapeutics (DSGN) Slips 0.7% as Shares Trade at Midpoint of Key Support-Resistance RangeArms Index - dars.gov.et
A biotech company's conference chat will be webcast live Sept. 9. - Stock Titan
Design Therapeutics (DSGN) Holds Above $15 as Shares Slip 0.92%Risk Parity Rebalance - vinanet.vn
DSGN Q2 2026 Earnings: Narrower-than-Expected Loss Highlights Operational Discipline in a Pre-Revenue Quarter - careplusvn.com
Marvell Technology, PayPal, Rubrik And Other Big Stocks Moving Lower In Friday’s Pre-Market Session - Sahm
Wall Street Moves on MAA, Rivian and Design Therapeutics: One Upgrade, One Target Trim and a Biotech on Watch - Yahoo Finance
Celea Therapeutics Will Present Phase 3 Trial Design for Idiopathic Pulmonary Fibrosis and Key Insights from a Deupirfenidone Drug-Drug Interaction Study at the Upcoming European Respiratory Society (ERS) Congress - Business Wire
Design Therapeutics Number of Employees 2026 | Employee Count & Headcount Data - Revelio Labs
DSGN Q2 2026 Earnings: Narrower-than-Expected Loss Lifts SharesFiscal Year Earnings - vinanet.vn
DSGN Q2 2026 Earnings: Narrower-Than-Expected Loss Drives 3.06% Stock GainMid-Term Outlook - Vinanet
Design Therapeutics Stock Price Forecast. Should You Buy DSGN? - StockInvest.us
Point72 discloses 3.8% Design Therapeutics (DSGN) stake totaling 2.37M shares - Stock Titan
Design Therapeutics (DSGN): Sirenia Capital discloses 9.5% beneficial ownership stake - Stock Titan
Design Therapeutics, Inc. $DSGN Shares Bought by Dimensional Fund Advisors LP - MarketBeat
Design Therapeutics, Inc. (NASDAQ:DSGN) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Design Therapeutics, Inc. $DSGN Shares Purchased by Sei Investments Co. - MarketBeat
DSGN Q2 2026 Earnings: Narrower-Than-Expected Loss Signals Cost DisciplinePreliminary Results - vinanet.vn
Renaissance Technologies LLC Buys 121,100 Shares of Design Therapeutics, Inc. $DSGN - MarketBeat
Design Therapeutics (DSGN) Rises 1.47% as Gene Therapy Plays Draw AttentionRectangle Pattern - dars.gov.et
Design Therapeutics, Inc. reports results for the quarter ended June 30Earnings Summary - TradingView
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22 - Moomoo
Design Therapeutics Q2 Net Loss Narrows - Moomoo
Design Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Design Therapeutics posts Q2 loss, updates clinical trials - Investing.com
Design Therapeutics (NASDAQ:DSGN) Announces Quarterly Earnings Results, Beats Estimates By $0.02 EPS - marketbeat.com
Design Therapeutics Q2 net loss narrower than expected - TradingView
Design Therapeutics reports $20.2M Q2 net loss, $207.4M cash as RESTORE-FA advances - TradingView
Design Therapeutics, Inc. 2Q 2026: Net loss $(20,165)K, EPS $(0.32) — 10-Q Summary - TradingView
Design Therapeutics Reports $20.2 Million Q2 Net Loss, Updates RESTORE-FA Trial - Moomoo
Design Therapeutics Provides RESTORE-FA Clinical Development Update and Reports Second Quarter 2026 Financial Results - marketscreener.com
Design Therapeutics Inc expected to post a loss of 34 cents a shareEarnings Preview - TradingView
Design Therapeutics Inc (DSGN) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Design Therapeutics (DSGN) to Announce Quarterly Earnings on Thursday - MarketBeat
Design Therapeutics (DSGN) Edges Higher as Stock Tests Key Resistance LevelImpulse Wave - careplusvn.com
A Deeper Dive Into Design Therapeutics (NASDAQ:DSGN) - Seeking Alpha
Design Therapeutics Inc (DSGN) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
DSGN|Design Therapeutics Inc|Price:13.990|Chg%:+0.220 - TradingKey
DSGN|Design Therapeutics Inc|Price:13.060|Chg%:+0.300 - TradingKey
Design Therapeutics Inc (DSGN) Institutional Confidence - TradingKey
Design Therapeutics Inc (DSGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Design Therapeutics Inc (DSGN) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Design Therapeutics Inc (DSGN) Balance Sheet - TradingKey
Design Therapeutics Inc (DSGN) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Design Therapeutics (DSGN) Edges Higher as Shares Test Key Resistance LevelsStock Buy Zone - Vinanet
Design Therapeutics, Inc. Revenue Breakdown – NASDAQ:DSGN - TradingView
DSGN|Design Therapeutics Inc|Price:11.780|Chg%:+0.150 - TradingKey
Edgewise Therapeutics, Inc. (EWTX) options chain - Yahoo Finance Singapore
We're Not Very Worried About Design Therapeutics' (NASDAQ:DSGN) Cash Burn Rate - Moomoo
Fuchs Dystrophy Pipeline 2026: Therapies Under Investigation, - openPR.com
3.06%
2.55%
자본화:
|
볼륨(24시간):